semaglutide – Talk Bio

Actionable Insights Powered by AI

Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26

2 weeks ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, JPM26, Mike Doustdar, Novo Nordisk, Obesity, semaglutide, Wegovy pill

Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide

JPM26: Novo Nordisk and Eli Lilly Compete Fiercely in Oral Obesity Treatments

2 weeks ago talkbio0Tagged eli lilly, JPM26, JPMHC, Novo Nordisk, oral obesity drugs, orglipron, semaglutide

Novo Nordisk; Eli Lilly; oral obesity drugs; JPM26; JPMHC; orglipron; semaglutide

CMS Unveils Negotiated Prices for Ozempic, Wegovy, and Other Drugs in Second Round of IRA Talks

2 months ago talkbio0Tagged drug price, Effectiveness, Inflation Reduction Act, Medicare Part D, Myasthenic Syndromes, Congenital, negotiation, Ozempic, Prices, semaglutide, Wegovy

CMS; Ozempic; Wegovy; Inflation Reduction Act; drug price negotiation; Medicare Part D; semaglutide; negotiated prices; 2027 effective date

Novo Nordisk’s Semaglutide Misses Key Goals in Closely-Watched Alzheimer’s Disease Phase 3 Trials

2 months ago talkbio0Tagged Alzheimer 's disease, Biological Markers, Clinical trial failure, EVOKE trial, Glucagon-Like Peptide 1, Mental deterioration, Novo Nordisk, Phase 3, Rybelsus, semaglutide

Novo Nordisk; semaglutide; Alzheimer’s disease; EVOKE trial; EVOKE+ trial; clinical trial failure; Rybelsus; GLP-1 drugs; phase 3; biomarkers; cognitive decline

Closed Loop Medicine Secures Additional Key GLP-1 Patent for Its AI-Based Dosing Platform: Powering Personalized, Direct-to-Patient Therapies

3 months ago talkbio0Tagged adaptive dosing, AI-based, Closed Loop Medicine, dosing, Glucagon-Like Peptide 1, incretin drugs, Legal patent, personalized therapies, semaglutide, WeDosify

Closed Loop Medicine; GLP-1; patent; AI-based dosing; personalized therapies; semaglutide; incretin drugs; WeDosify; adaptive dosing; direct-to-patient

Lilly’s Oral GLP-1, Orforglipron, Achieves Two New Clinical Wins in Type 2 Diabetes

4 months ago talkbio0Tagged ACHIEVE-1, ATTAIN-2, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Effectiveness, Eli Lilly, Farxiga, Glucagon-Like Peptide 1, Oral cavity, orforglipron, regulatory submission, Safety, semaglutide, Weight Loss

Lilly; Orforglipron; oral GLP-1; type 2 diabetes; clinical trial; weight loss; regulatory submission; ACHIEVE-1; ATTAIN-2; semaglutide; Farxiga; efficacy; safety

Eli Lilly’s Oral GLP-1 Orforglipron Outperforms Semaglutide in Diabetes and Weight Loss Trials

4 months ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Eli Lilly, Glucagon-Like Peptide 1, Nordisk, Oral cavity, orforglipron, semaglutide, Weight Loss

Lilly; orforglipron; oral GLP-1; semaglutide; type 2 diabetes; weight loss; phase 3 trial; Novo Nordisk

ICER Draft Report: High-Cost GLP-1 Obesity Drugs Deemed Cost-Effective—Affordability Still a Concern

5 months ago talkbio0Tagged Affordability, cardiovascular benefits, Cost-Effectiveness, CREM gene, Glucagon-Like Peptide 1, Health Policy, Obesity, semaglutide, tirzepatide, value-based pricing

ICER; GLP-1; semaglutide; tirzepatide; obesity drugs; cost-effectiveness; health policy; affordability; value-based pricing; cardiovascular benefits

FDA Shifts Approach on GLP-1 Compounding: Announces Consumer Green List Instead of Immediate Crackdown

5 months ago talkbio0Tagged Compound, Consumer Safety, Drug shortages, Glucagon-Like Peptide 1, green list, import alert, Regulation, semaglutide, United States Food and Drug Administration

FDA; GLP-1; compounding; green list; drug shortages; semaglutide; tirzepatide; import alert; consumer safety; regulation

FDA Grants Wegovy 3rd Indication: First GLP-1 Approved for MASH with Moderate-to-Advanced Liver Scarring

5 months ago talkbio0Tagged Accelerated, Approved, Fibrosis, Liver, MASH, noncirrhotic, Nordisk, Product containing glucagon-like peptide 1 receptor agonist (product), semaglutide, United States Food and Drug Administration, Wegovy

Wegovy; FDA approval; MASH; semaglutide; GLP-1 receptor agonist; liver fibrosis; Novo Nordisk; ESSENCE trial; noncirrhotic; accelerated approval